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Brain-derived neurotrophic factor (BDNF) has important
functions in the development of the nervous system and
in brain plasticity-related processes such as memory,
learning, and drug addiction. Despite the fact that the
function and regulation of rodent BDNF gene expression
have received close attention during the last decade,
knowledge of the structural organization of mouse and
rat BDNF gene has remained incomplete. We have iden-
tiﬁed and characterized several mouse and rat BDNF
transcripts containing novel 50 untranslated exons and
introduced a new numbering system for mouse and rat
BDNF exons. According to our results both mouse and
rat BDNF gene consist of eight 50 untranslated exons
and one protein coding 30 exon. Transcription of the gene
results in BDNF transcripts containing one of the eight 50
exons spliced to the protein coding exon and in a tran-
script containing only 50 extended protein coding exon. We
also report the distinct tissue-speciﬁc expression proﬁles
of each of the mouse and rat 50 exon-speciﬁc transcripts in
different brain regions and nonneural tissues. In addition,
we show that kainic acid-induced seizures that lead to
changes in cellular Ca
2+ levels as well as inhibition of DNA
methylation and histone deacetylation contribute to the dif-
ferential regulation of the expression of BDNF transcripts.
Finally, we conﬁrm that mouse and rat BDNF gene loci do
not encode antisense mRNA transcripts, suggesting that
mechanisms of regulation for rodent and human BDNF
genes differ substantially. V V C 2006 Wiley-Liss, Inc.
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Brain-derived neurotrophic factor (BDNF) is a mem-
ber of the neurotrophin family consisting of small secreted
proteins that play important roles in the development of
the nervous system in vertebrates (for recent reviews see
Bibel and Barde, 2000; Binder and Scharfman, 2004; Chao
et al., 2006). BDNF supports the survival and differentia-
tion of speciﬁc populations of embryonic neurons in vivo,
and growing evidence indicates that BDNF is also
involved in several functions in adulthood, including neu-
ronal homeostasis and brain plasticity-related processes
such as memory, learning (Tyler et al., 2002; Yamada
et al., 2002), and drug addiction (Bolanos and Nestler,
2004). Alterations in BDNF expression in speciﬁc neuron
subpopulations contribute to various pathologies, includ-
ing depression, epilepsy, and Alzheimer’s, Huntington’s,
and Parkinson’s diseases (Bibel and Barde, 2000; Murer
et al., 2001; Binder and Scharfman, 2004; Castren, 2004;
Cattaneo et al., 2005; Russo-Neustadt and Chen, 2005).
In addition to BDNF, the neurotrophin family in-
cludes nerve growth factor, neurotrophin-3, and neuro-
trophin-4/5 (Binder, 2004). All neurotrophins bind to
p75
NGFR receptor but selectively interact with their indi-
vidual high-afﬁnity protein kinase receptors of the trk
(tropomyosin-related kinase) family (Kaplan and Miller,
2000; Chao, 2003; Teng and Hempstead, 2004). BDNF
mediates its biological effects via TrkB and p75
NGFR
receptors. Binding of mature BDNF protein to TrkB and
p75
NGFR promotes cell survival, neurite outgrowth, syn-
aptic transmission, plasticity, and cell migration (Dechant
and Barde, 2002). Uncleaved precursor BDNF protein
(pro-BDNF) has altered binding characteristics and dis-
tinct biological activity in comparison with mature
BDNF protein (Lee et al., 2001; Teng et al., 2005).
In mouse and rat, BDNF mRNA is expressed
throughout development and differentially in adult tissues
(Ernfors et al., 1990; Hofer et al., 1990; Hohn et al.,
1990). In the brain, BDNF mRNA and protein expres-
sion becomes detectable during embryonic development,
reaching the highest levels by days 10–14 postnatally and
decreasing thereafter. In the adult animal, BDNF is ex-
pressed throughout the brain, with the highest levels in
the neurons of hippocampus (Ernfors et al., 1990; Hofer
et al., 1990; Kawamoto et al., 1996; Conner et al., 1997;
Yan et al., 1997). Neuronal BDNF expression is affected
by many stimuli, such as g-aminobutyric acid (GABA)-
ergic and glutamatergic neurotransmission and membrane
depolarization through calcium-mediated pathways (Zafra
et al., 1990, 1991; Ghosh et al., 1994; Shieh and Ghosh,
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' 2006 Wiley-Liss, Inc.1999; West et al., 2001). BDNF gene expression is con-
trolled by multiple activity-dependent and tissue-speciﬁc
promoters. Four BDNF promoters have been previously
identiﬁed in rat (Metsis et al., 1993; Timmusk et al.,
1993; Timmusk et al., 1995), each driving the transcrip-
tion of BDNF mRNAs containing one of the four 50
noncoding exons (I, II, III, or IV) spliced to the common
30 coding exon. Several transcription factors contributing
to the regulation of BDNF promoters have been charac-
terized. Among these factors are cAMP-responsive ele-
ment binding protein (CREB; Shieh et al., 1998; Tao
et al., 1998; Tabuchi et al., 2002) and upstream stimula-
tory factors 1/2 (USF1/2; Tabuchi et al., 2002; Chen
et al., 2003b), which regulate BDNF promoters I and III.
In addition, calcium-responsive transcription factor (CaRF)
has been found to mediate BDNF transcription through
binding to BDNF promoter III upon neuronal activation
(Tao et al., 2002). Chromatin remodeling by DNA methyl-
ation and histone deacetylation also plays an important role
in cell-speciﬁc and activity-dependent regulation of BDNF
gene by recruiting global repressors such as REST/NRSF
t op r o m o t e rI I( P a l me ta l . ,1 9 9 8 ;T i m m u s ke ta l . ,1 9 9 9 ;
Zuccato et al., 2003) and MeCP2 to promoter III (Chen
et al., 2003a; Martinowich et al., 2003).
Unraveling the regulation of BDNF gene expression
is important for understanding its contribution to nervous
system function and pathology. Provided that BDNF
actions are most frequently modeled in rodents, detailed
knowledge of the structural organization of rodent BDNF
genes would be imperative. We undertook this study to
specify the structure and expression of BDNF gene in
mouse and rat. We show that rodent BDNF gene structure
and expression are more complex than initially characterized
(Timmusk et al., 1993) and that novel, as yet unidentiﬁed
regulatory sequences may contribute to cell-speciﬁc and ac-
tivity-dependent regulation of rodent BDNF expression.
MATERIALS AND METHODS
DNA and Amino Acid Sequence Analysis
Mouse and rat BDNF gene structure in silico analysis was
performed using genomic, mRNA and EST databases (http://
www.ncbi.nlm.nih.gov and http://genome. ucsc.edu). Align-
ment tools available at http://www.ncbi. nlm.nih.gov as well as
software provided by the BIIT group at the University of Tartu,
Estonia, were used for homology searches and analysis. AntiHunter
software (available at http://bio.ifom-ﬁrc.it/ANTIHUNTER/)
was used to search for opposite-strand transcripts in mouse and
rat BDNF genomic region.
RNA Isolation, cDNA Synthesis, RT-PCR
Total RNA from developing and adult mouse and rat total
brain and brain regions and nonneural tissues was puriﬁed by
RNAwiz (Ambion, Austin, TX) as recommended by the manu-
facturer. DNase treatment of total RNA was perfomed by using a
Turbo DNA-Free Kit (Ambion) according to the manufacturer’s
instructions. Five micrograms of total RNA from different tissues
was used for ﬁrst-strand synthesis using oligo(dT) and SuperScript
III First-Strand synthesis system (Invitrogen, Carlsbad, CA). To
analyze expression of BDNF transcripts, reverse primer speciﬁc
for 30 BDNF coding exon and forward primers speciﬁc for 50
noncoding exons were used. To identify homologues of human
antisense BDNF exons in mouse and rat, primers were designed
corresponding to mouse and rat BDNF genomic regions that
showed signiﬁcant homology with human exons. Total RNA
was normalized to the expression of ubiquitously expressed
HPRT gene. All primers used in the study are listed below,
where m designates mouse, r, rat; h, human; for, forward; rev,
reverse; and Arabic numbers BDNF exons as follows: mrBDNFI,
GTGTGACCTGAGCAGTGGGCAAAGGA; mrBDNFII,
GGAAGTGGAAGAAACCGTCTAGAGCA; mBDNFIII,
GCTTTCTATCATCCCTCCCCGAGAGT; rBDNFIII,
CCTTTCTATTTTCCCTCCCCGAGAGT; mrBDNFIV,
CTCTGCCTAGATCAAATGGAGCTTC; mrBDNFV,
CTCTGTGTAGTTTCATTGTGTGTTC; mBDNFVI,
GCTGGCTGTCGCACGGTTCCCATT; rBDNFVI,
GCTGGCTGTCGCACGGTCCCCATT; mrBDNFVII,
CCTGAAAGGGTCTGCGGAACTCCA; mrBDNFVIII,
GTGTGTGTCTCTGCGCCTCAGTGGA; mBDNFIXA,
CCCAAAGCTGCTAAAGCGGGAGGAAG; rBDNFIXA,
CCAGAGCTGCTAAAGTGGGAGGAAG; hmrHPRT for,
GATGATGAACCAGGTTATGAC; hmrHPRTrev, GTC-
CTTTTCACCAGCAAGCTTG; and mrBDNFrev, GAA-
GTGTACAAGTCCGCGTCCTTA.
To analyze expression of mouse and rat exons I–IV-,
exon VI-, and exon IXA-speciﬁc transcripts, cDNA was ampli-
ﬁed in a total volume of 25 ml with 35 cycles of PCR using
HotFire polymerase system (Solis BioDyne, Estonia). An anneal-
ing temperature of 608C was used for all primer combinations.
Because of relatively low expression levels of BNDF mRNAs
containing exons V, VII, and VIII, a more robust HotStartTaq
Master Mix kit (Qiagen, Chatsworth, CA) was used for cDNA
ampliﬁcation for 40–45 PCR cycles. All RT-PCR reactions
were performed in triplicate. PCR products were resolved in
1.2% agarose gel and visualized by staining with ethidium bro-
mide. PCR fragments were subsequently excised from the gel,
cloned by using pCRII-TOPO cloning system (Invitrogen), and
subjected to sequence analysis.
50 RACE Analyses of Transcription Initiation Sites
To determine the transcription start sites of novel BDNF
transcripts, 50 rapid ampliﬁcation of cDNA ends (RACE) was per-
formed by using the GeneRacer kit (Invitrogen) according to the
manufacturer’s instructions. PCR ampliﬁcation was performed
with aHotStartTaqMaster Mix kit(Qiagen)and GeneRacer50 for-
ward primer and reverse primers speciﬁc for exons III, V, VII, VIII,
and IXA. Then, nested PCR was performed to increase the spec-
iﬁcity and sensitivity of RACE by using GeneRacer 50 nested
primer and nested primers speciﬁc for exons III, V, VII, VIII,
and IXA. RACE products were analyzed in a 2% gel and cloned
into the pCRII-Topo vector (Invitrogen) for sequence analysis.
Primers used for RACE analysis are listed below: rBDNFIIIR-
ACE,TCAATGAAGCATCCAGCCCGGCA;rBDNFIIINested,
CGGAACTCTCGGGGAGGGAAAATA; rBDNFVRACE,
GAACACACAATGAAACTACACAGAG; rBDNFVIIRACE,
CTAAAGAGGTGCGCTGGATGGACAGAG; rBDNFVII-
Nested, GGACCTGGAGTTCCGCAGACCCTTT; rBDNF-
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rBDNFVIIINested, GAGACACACACCACAGCCTTTCTC;
rBDNFIXARACE, GAGTAAACGGTTTCTAAGCAA-
GTG; and rBDNFIXANested, CTTCCTCCCACTTTAG-
CAGCTCTG.
Cell Culture and Animal Experiments
Rat glioma C6 and mouse neuroblastoma Neuro2A cells
were plated 16 hr before treatment in DMEM (Invitrogen) con-
taining 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100
mg/ml streptomycin). Trichostatin A (TSA) and 5-aza-20-deoxy-
cytidine (5AzadC) were purchased from Sigma-Aldrich (St.
Louis, MO). Neuro-2A and C6 cells were treated for 48 hr with
5AzadC (1 mM) or with TSA (333 nM) to analyze the effects of
5AzadC and TSA on the expression of BDNF.
Adult male Sprague-Dawley rats were injected with the
glutamate analog kainic acid as previously described (Metsis
et al., 1993). Animals were sacriﬁced 1, 3, 6, 12, and 24 hr
posttreatment. Total RNA from hippocampi was extracted by
using RNAwiz RNA Isolation Reagent (Ambion) according
to the manufacturer’s recommendations. All animal experi-
ments were performed according to the norms of the local Eth-
ical Committee of Animal Experimentation.
RESULTS
New Nomenclature for Mouse and
Rat BDNF Gene
BDNF gene is transcribed from multiple promoters
located upstream of distinct 50 noncoding exons to pro-
duce a heterogeneous population of BDNF mRNAs.
Although this conserved feature of BDNF has been
described for several species, including human (Liu et al.,
2005), mouse (Hayes et al., 1997), rat (Timmusk et al.,
1993), and zebraﬁsh (Heinrich and Pagtakhan, 2004),
detailed analyses of rodent BDNF gene structure have not
been performed. In rat, four 50 noncoding exons (I–IV)
that are spliced to the common 30 coding exon (Fig. 1A)
have previously been identiﬁed (Timmusk et al., 1993).
For mouse, only homologues of rat BDNF exons I and II
have been reported (Hayes et al., 1997). In silico analysis
of mouse and rat BDNF gene structure performed in the
present study showed that BDNF exons III and IV are
present and expressed in mouse as well. Moreover, a
number of EST and mRNA sequences aligned to the
locations of potential novel BDNF exons and the respec-
tive sequences turned out to be highly conserved in rat
and mouse genome. Furthermore, analysis of BDNF 50
RACE products from human hippocampal RNA re-
vealed additional novel exons (Kazantseva et al., unpub-
lished), the sequences of which were also conserved in
mouse and rat genomes. Identiﬁcation of rodent BDNF
transcripts containing novel exons by RT-PCR and sub-
sequent cloning and sequencing conﬁrmed the bioinfor-
matic analyses data. Together our results show that both
rat and mouse BDNF gene contains eight 50 noncoding
exons and one 30 protein coding exon. All exon–intron
junctions display conventional splice-donor and -acceptor
sites. A new nomenclature was assigned to mouse and rat
BDNF exons (Fig. 1B). In both mouse and rat genomes,
the locations of novel BDNF exons are as following: exon
III (corresponding to rat exon Ia described by Bishop
et al., 1994) is located 0.6 kb downstream of previously
described exon II, exon V is 0.25 kb downstream of exon
IV (exon IV is the former exon III according to Timmusk
et al., 1993), exon VII is located 0.6 kb downstream of
exon VI (exon VI corresponds to exon IV in Timmusk
et al. 1993), exon VIII is 13.5 kb upstream of the protein
coding exon, and exon IXA is a 50 extended variant of the
protein coding exon (Fig. 1B). Homology of human and
rodent BDNF 50 exons ranges from 95% to 45%, reaching
95% for exon I, 93% for exon II, 62% for exon III, 91%
for exon IV, 86% for exon VI (corresponds to exon V in
human according to Liu et al., 2005), and 45% for exon
VII (corresponds to exon VIA in human according to Liu
et al., 2005). All exons that have been deﬁned in human
(Liu et al., 2005) are also expressed in mouse and rat,
except for human exons VIIB and VIII. Rodent exons V,
VIII, and IXA have not been previously described in
human (Liu et al., 2005), but according to our data these
exons are expressed in human as well (Kazantseva et al.,
unpublished). Rat BDNF gene has been suggested to
undergo cryptic splicing within exon II (Timmusk et al.,
1995). In agreement with the recently updated version of
GenBank’s submission (AY057907), our results show that
usage of alternative splice donor sites (A, B, and C in Fig.
1B) within BDNF exon II leads to three different exon II
transcript variants in both in mouse and rat.
Expression Analysis of Mouse and
Rat BDNF Transcripts
Rat BDNF transcripts containing exons I, II, IV
(former III), and VI (former IV) and their tissue-speciﬁc
expression proﬁles have previously been described (Tim-
musk et al., 1993), whereas there are no data on the
expression of the novel rat BDNF exons V, VII, VIII,
and IXA, and only limited data are available on the
expression patterns of rat exon III (Bishop et al., 1994).
Furthermore, although promoter regions upstream of
mouse BDNF exons I and II have been described (Hayes
et al., 1997), no data are available for the expression of
mouse BDNF transcripts containing exons I–IXA. In the
present work, RT-PCR analysis of the expression proﬁles
of all BDNF transcripts was carried out in developing and
adult brain as well as in peripheral tissues of mouse and
rat (Fig. 2).
Expression of rat exon I BDNF mRNA, which was
previously described as a brain-speciﬁc transcript (Tim-
musk et al., 1993), was also observed at low levels in
several nonneural tissues, including testis, lung, thymus,
liver, and spleen (Fig. 2B). Expression of mouse exon I
transcripts was detected in addition to brain only in thy-
mus (Fig. 2A). In adult mouse and rat brain, BDNF exon
I mRNAs were expressed in all regions studied, with the
lowest levels in cerebellum. In developing mouse and rat
brain, low levels of BDNF exon I transcripts were ex-
pressed at embryonic (E) days 13 and 15, the expression
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onic day 21 in rat and decreased slightly during postnatal
development (Fig. 2A,B). BDNF exon II mRNA splice
variants A, B, and C revealed differential expression pat-
terns in brain both in mouse and in rat, and their expres-
sion was not detected in peripheral tissues. In cerebellum,
exon IIA transcript was the most abundant; in hippocam-
pus, all three exon II splice variants were expressed at
similar levels. Overall brain-speciﬁc expression pattern of
mouse and rat novel BDNF exon III transcripts resembled
that of BDNF exon II (Fig. 2A,B). In murine nonneural
tissues, low levels of exon III transcripts were detected
only in spleen and kidney, and, in rat, exon III transcripts
were detected in thymus. BDNF exon IV and exon VI
mRNAs (formerly exons III and IV, Timmusk et al.,
1993) were observed at signiﬁcant levels in developing
mouse and rat brain already at E13, the earliest develop-
mental stage studied. Both in mouse and in rat, BDNF
exon IV and exon VI mRNA levels increased gradually
during embryonic and postnatal development and de-
creased slightly in adult brain. In adult brain, exon IV and
exon VI transcripts were detected in all analyzed brain
regions both in mouse and in rat. Exon IV and exon VI
transcripts exhibited wide patterns of expression in mouse
and rat nonneural tissues, with the highest levels in heart
and lung (Fig. 2A,B).
In both mouse and rat, BDNF novel exons V, VII,
and VIII, were expressed at relatively low levels during
brain development, broadly in adult peripheral tissues,
and differentially in adult brain regions (Fig. 2A,B). In
spite of the fact that mouse BDNF mRNA containing
exons VII and VIII in the same transcript has been submit-
ted to NCBI GenBank (AY231132), we failed to detect
similar mRNAs in any of mouse or rat tissue studied.
Expression of the novel BDNF exon IXA tran-
scripts was detected in rodent brain during embryonic
Fig. 1. Exon/intron structure and alternative transcripts of mouse and
rat BDNF genes. A: Rat BDNF gene structure as described by Tim-
musk et al. (1993). Exons are shown as boxes and introns are shown as
lines. B: The new arrangement of exons and introns of mouse and rat
BDNF genes as determined by analyzing genomic and mRNA sequence
data using bioinformatics, 50 RACE, and RT-PCR. The schematic rep-
resentation of BDNF transcripts in relation to the gene is shown below
the gene structure. Protein coding regions are shown as solid boxes and
untranslated regions are shown as open boxes. Each of the eight 50
untranslated exons is spliced to the common 30 protein coding exon IX.
In addition, transcription can be initiated in the intron before the protein
coding exon, which results in IXA transcripts containing 50 extended
coding exon. Each transcription unit may use one of the two alternative
polyadenylation signals in the 30 exon (arrows). For exon II, three differ-
ent transcript variants, IIA, IIB, and IIC, are generated as a result of using
alternative splice-donor sites in exon II (arrows marked A, B, and C).
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brain, exon IXA-containing transcripts were expressed
at similar levels in all brain regions (Fig. 2A), whereas, in
rat adult brain, exon IXA expression was detected at
high levels in hippocampus, olfactory bulb, colliculus,
and cerebellum and at lower levels in cortex and pons
Fig. 2. Expression analysis of mouse and rat BDNF mRNAs. Semiquantitive RT-PCR analysis of tis-
sue-speciﬁc expression of mouse (A) and rat (B) BDNF transcripts and control HPRT mRNA was
performed in developing and adult brain and in peripheral organs. E, embryonic day; P, postnatal day.
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levels of exon IXA transcripts were observed in heart
and lung.
Identiﬁcation of the Transcription Start Sites for
BDNF New Exons III, V, VII, and VIII in Rat
The transcription initiation sites for rat BDNF exons
I, II, IV, and VI have been determined earlier (Timmusk
et al., 1993). To identify the transcription start sites for
novel BDNF transcripts, 50 rapid ampliﬁcation of cDNA
ends (50 RACE) from rat hippocampal RNA was per-
formed by using antisense primers speciﬁc for exons III,
V, VII, VIII, and IXA. Sequencing analysis of different
RACE clones showed that major transcription initiation
sites are located at 152 bp and 230 bp for exon III, at 81 bp
for exon V, at 277 bp and 286 bp for exon VIII upstream
of the 30 end of the respective exon, and at 476 bp and
363 bp for exon IXA upstream of the major splice site of
this exon (Fig. 3). None of the identiﬁed 50 exons con-
tains upstream open reading frames, so the usage of these
50UTRs will apparently not affect amino acid composition
Fig. 3. Identiﬁcation of the transcription start sites for BDNF new
exon III, V, VII, VIII, and IXA mRNAs in rat. 50 Rapid ampliﬁcation
of cDNA ends (50 RACE) was performed to determine the transcrip-
tion start sites for novel BDNF transcripts. Major transcription initiation
sites (short arrows) are located at 152 bp and 230 bp for exon III (arrows
marked A and B), at 81 bp for exon V and at 277 bp and 286 bp for
exon VIII (arrows marked A and B) upstream of the 30 end of the re-
spective exon and at 476 bp and 363 bp upstream of the major splice
acceptor site of the coding exon (asterisk) for exon IXA. For exon VII,
the 50end of the longest EST is shown as a putative transcription initia-
tion site, because 50 RACE did not result in any speciﬁc products as a
result of very low levels of exon VII transcripts. Exon sequences are in
boldface; intron sequences are in lowercase letters. The locations of pri-
mers that were used in 50 RACE are indicated with long arrows.
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levels, we failed to map the transcription start site for rodent
BDNF exon VII. However, 50 RACE analysis of rodent
exon VII homologue in human showed that transcription
initiation site for this exon is located at 285 bp upstream
of its 30 end (Kazantseva et al., unpublished). These data
strongly suggest that, similarly to BDNF exon I, II, IV, and
VI mRNAs (Timmusk et al., 1993), novel exon III, V,
VII, VIII, and IXA mRNAs are also transcribed from sepa-
rate promoters.
Differential Regulation of BDNF Expression by
DNA Methylation and Histone Deacetylation
Provided that methylation of the cytosine residues
in the CpG dinucleotides in genome and posttranslational
modiﬁcations of histones in the nucleosome establishes
epigenetic codes for gene regulation in different tissues,
including nervous system (Hsieh and Gage, 2004; Ballas
and Mandel, 2005), we investigated the potential role of
chromatin structure on transcriptional activity of BDNF
promoters. By treating rat C6 glioma cells and mouse
Neuro2A neuroblastoma cells with the DNA methyltrans-
ferase inhibitor 5AzadC or with the histone deacetylase
(HDAC) inhibitor TSA for 48 hr, we examined the role
of DNA methylation and histone acetylation, respectively,
in the regulation of BDNF gene expression.
We observed robust activation of the expression of
BDNF exon I and IV as well as novel exon V, VIII, and
IXA transcripts in rat C6 glioma cells after 5AzadC treat-
ment (Fig. 4). Expression of exons III and VI in C6 cells
was moderately induced by inhibition of DNA methyla-
tion. Expression of BDNF exon I and exon III transcripts
in Neuro2A cells was signiﬁcantly induced following
5AzadC treatment, whereas there was no change in the
levels of other BDNF mRNAs (Fig. 4). In Neuro2A cells,
TSA treatment failed to relieve repression of any of the
BDNF promoters. However, in C6 cells, inhibition of
histone deacetylation by TSA increased the levels of
BDNF exon III, exon VII, and exon IXA transcripts.
Muscarinic acetylcholine receptor gene M4 was used as a
reference because its expression has been shown to be
regulated by 5AzadC in various cell lines, other than C6
and Neuro2A, in a cell-type-speciﬁc manner (Lunyak
et al., 2002; Wood et al., 2003). Our ﬁndings suggest that
DNA methylation and histone deacetylation could play a
role in silencing of BDNF gene in a promoter- and cell-
speciﬁc manner both in C6 and Neuro2A cells.
Activity-Dependent Regulation of Rat BDNF
Exon-Speciﬁc mRNAs in the Hippocampus by
Kainic Acid-Induced Seizures
Glutamate analogue kainic acid induces a rise in in-
tracellular Ca
2+ levels and differential activation of four
previously characterized BDNF promoters in the hippo-
campus and cerebral cortex of adult rat brain (Timmusk
et al., 1993). We examined whether expression of the
BDNF mRNAs containing novel 50 exons is regulated by
kainic acid 1, 3, 6, 12, and 24 hr after drug administra-
tion. The results revealed differential regulation patterns
for BDNF transcripts. BDNF exon I and IV transcripts
(exons I and III according to Timmusk et al., 1993) have
previously been characterized as the most highly induced
BDNF mRNAs in response to kainic acid treatment. It
was remarkable that in our experiments not only were
these BDNF transcripts induced by kainate but also the
levels of novel exon V, VII, VIII, and IXA mRNAs were
up-regulated peaking at 3–6 hr posttreatment and rapidly
down-regulated to basal levels thereafter (Fig. 5). The
levels of exon IV transcripts remained elevated at 3–24 hr
posttreatment. BDNF transcripts with exon IIA, IIB, and
IIC exhibited differential expression proﬁles in response
to kainite treatment. The levels of exon IIC transcripts
were markedly elevated at 3 hr, peaked at 6 hr, and de-
creased at 12–24 hr after kainate treatment. Expression
levels of exon 2A and exon 2B transcripts increased mod-
erately at 3 hr, dropped at 6 hr, and reached basal levels at
24 hr posttreatment (Fig. 5). In contrast, the expression
levels of BDNF exon III and exon VI mRNAs did not
change at any time point studied (Fig. 5). These results
agree with the previous reports on the transcript-speciﬁc
regulation of rat BDNF mRNAs in response to kainate-
induced seizures (Timmusk et al., 1993; Sathanoori et al.,
Fig. 4. Differential regulation of BDNF gene expression by DNA
methylation and histone deacetylation. The role of DNA methylation
in transcriptional activity of BDNF promoters was investigated by
treating rat C6 glioma and mouse Neuro2A neuroblastoma cells with
1 mM 5-Aza-deoxycytidine (5AzadC) for 48 hr. The effects of inhibi-
tion of histone deacetylation was studied by treating Neuro2A and C6
cells with 300 nM trichostatin A (TSA) for 48 hr. Muscarinic acetyl-
choline receptor M4 gene and constitutive hypoxanthine-phosphori-
bosyltransferase (HPRT) gene were used as reference genes.
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BDNF mRNAs are differentially regulated by kainic acid.
Our data strongly suggest that as yet unexplored regula-
tory elements within BDNF gene contribute to the activ-
ity-dependent regulation of BDNF mRNA expression.
Antisense-BDNF Transcripts Are Not
Expressed in Mouse and Rat
It was shown recently (Liu et al., 2005) that protein
noncoding antisense transcripts are expressed from human
BDNF gene locus. Analyses of mouse and rat BDNF gene
loci with the AntiHunter software tool (Lavorgna et al.,
2004) did not reveal any BDNF antisense transcripts from
EST databases. Moreover, alignment of human antisense
BDNF exons sequences with mouse and rat EST databases
at NCBI did not reveal any rodent ESTs homologous to
human antisense BDNF transcripts. Failure to ﬁnd anti-
sense ESTs transcribed from mouse and rat BDNF gene
loci could be explained by the fact that, although EST
databases are growing rapidly, they are still undersampling
the full mammalian transcriptome. Therefore, we aligned
the sequences of human antisense BDNF exons with the
respective regions of mouse and rat BDNF genomic
sequence. Interestingly, sequences with signiﬁcant homol-
ogy to human antisense exons, though present in chim-
panzee genome, were missing from mouse and rat
genomes. RT-PCR analysis with mouse- and rat-speciﬁc
primers annealing to the very short regions of homology
with human antisense transcripts failed to detect expression
of antisense BDNF transcripts in mouse and rat tissues.
Therefore, we concluded that antisense BDNF transcripts
are human- or primate-speciﬁc, as was proposed earlier by
Liu and colleagues (2005).
DISCUSSION
Since the puriﬁcation of BDNF protein, deﬁnitive
evidence has emerged for its central role in mammalian
brain development, physiology, and pathology. However,
the structural organization of rodent BDNF gene has not
been revisited since four 50 exons were ﬁrst discovered and
nomenclature of exons established for rat BDNF gene
(Timmusk et al., 1993). This numeration of BDNF exons
is currently widely used by the scientiﬁc community. In
the present work, we show, however, that mouse and rat
BDNF gene structure is much more complex than was
accepted before. According to our data, mouse and rat
BDNF genes consist of a common 30 exon that encodes
the pro-BDNF protein and at least eight 50 noncoding
exons (exons I–VIII). In each BDNF transcript, one 50
exon is spliced to the protein coding exon. All 50 exons are
controlled by distinct promoters as evidenced by our
RACE analysis of the 50 ends of these exons, as well as
expression analysis data. In addition, we identiﬁed a novel
BDNF transcript both in mouse and in rat that contains
only exon IXA, the 50 extended protein coding exon.
Here we suggest a new numbering system for mouse and
rat BDNF exons. With regard to the old nomenclature
(Timmusk et al., 1993), former exon III corresponds to
exon IV, previous exon IV is now exon VI, and the cod-
ing exon previously called exon V is now exon IX.
Pro-BDNF, a 32-kDa precursor, undergoes cleavage
to release mature 14-kDa BDNF protein as well as a minor
truncated form of the precursor (28 kDa). Secreted pro-
BDNF activates a heteromeric receptor complex of p75
and sortilin to initiate cell death (Teng et al., 2005) and
binds to p75 in hippocampal neurons to enhance long-
term depression (Woo et al., 2005). Studies suggest that
proneurotrophins account for a signiﬁcant amount of the
total neurotrophins secreted extracellularly, particularly in
CNS neurons (Farhadi et al., 2000; Mowla et al., 2001). In
mouse, rat, and human, exon I transcripts contain an in-
frame AUG that can serve as an alternative translation ini-
tiation codon, extending the prepro- region of BDNF by
eight amino acids (Timmusk et al., 1993). It can be
hypothesized that additional amino acids in the N-termi-
nus of prepro-BDNF can affect the intracellular trafﬁcking
of BDNF and play a role in pro-BDNF secretion. In
human, BDNF 50 exons VIB and VII (according to Liu
et al., 2005) can contribute to alternative BDNF protein
isoforms, because exon VIB can add 15 amino acids to the
N-terminus of prepro-BDNF, and exon VII can undergo
alternative in-frame splicing leading to the mature BDNF
protein isoform that lacks 48 amino acids internally (Liu
et al., 2005). None of the novel rodent BDNF exons in-
Fig. 5. Activity-dependent regulation of BDNF exon-speciﬁc
mRNAs in rat hippocampus by kainic acid-induced seizures. The
effect of kainate-induced seizures on the expression of different BDNF
transcripts in the hippocampus of adult rat brain was examined. Adult
rats were injected subcutaneously with kainic acid (8 mg per kg body
weight) and sacriﬁced 1, 3, 6, 12, and 24 hr posttreatment. Total
RNA was extracted, and semiquantitative RT-PCR was performed.
Untreated rat hippocampus RNA was used as a control.
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scripts translation is initiated from the BDNF coding exon.
BDNF is the most abundant and widely distributed
neurotrophin in the mammalian CNS. In addition to re-
ﬁning expression patterns of BDNF transcripts that have
been identiﬁed earlier, results of this study also show that
mouse and rat BDNF novel exons III, V, VII, VIII, and
IXA are differentially expressed in adult brain and in pe-
ripheral tissues. In general, exons that are closely located
in the genome are expressed in a similar manner: exons I,
II, and III have brain-enriched expression patterns and
exons IV, V, and VI are widely expressed also in nonneu-
ral tissues. However, 50 RACE analysis of transcription
initiation sites of rat and mouse BDNF new exons and in
silico analysis of the regions upstream of these exons (data
not shown) suggest that their expression is driven by dis-
tinct novel tissue-speciﬁc and development- and activity-
regulated promoters.
It has been established earlier by using different cellu-
lar and animal models that BDNF gene is regulated by
neural activity through calcium-mediated pathways (Shieh
and Ghosh, 1999; West et al., 2001; Mellstrom et al.,
2004) and that BDNF transcripts containing exons I, II,
and IV are differentially regulated. BDNF exon I and exon
IV transcripts (exons I and III according to Timmusk
et al., 1993) have previously been characterized as the
most highly induced BDNF mRNAs in response to kainate
treatment and KCl-mediated membrane depolarization in
embryonic cortical neuron cultures (Tao et al., 1998). Sev-
eral calcium-responsive elements and transcription factors
binding to these elements have been characterized in the
promoter regions upstream of these exons (Timmusk et al.,
1999; Tabuchi et al., 2002; Tao et al., 2002; Chen et al.,
2003b). Here we show that BDNF exon V, exon VII,
exon VIII, and exon IXA transcripts are also regulated by
kainic acid and that the induction magnitude is comparable
to that of BDNF exon I and IV transcripts. In light of our
ﬁndings, it is attractive to speculate that differential regula-
tion of nine BDNF exon mRNAs would become apparent
in different neurodegenerative diseases in which BDNF
levels are altered (Phillips et al., 1991; Mogi et al., 1999;
Parain et al., 1999; Zuccato et al., 2001). Also, differential
regulation of BDNF mRNAs can take place for example in
depression, stress, exercise, and learning (Cotman and
Berchtold, 2002; Tyler et al., 2002; Hashimoto et al., 2004;
Russo-Neustadt and Chen, 2005). Future characterization
of the regulatory sequences and transcription factors media-
ting regulation of novel BDNF transcripts in different dis-
ease models is important for understanding BDNF gene
regulation and its contribution to pathology.
The role of chromatin remodeling in the activity of
different BDNF promoters has been investigated in several
recent studies. Neuronal activity-dependent activation of
BDNF gene is mediated by decreased CpG methylation of
BDNF promoter IV and release of a repressor complex
containing methyl-cytosine binding protein MeCP2, his-
tone deacetylases HDAC1 and HDAC2, and corepressor
mSin3A (Chen et al., 2003a; Martinowich et al., 2003). It
has also been shown that histone modiﬁcations at speciﬁc
BDNF promoters are involved in chromatin remodeling
during electroconvulsive seizures (Tsankova et al., 2004)
and cocaine-induced plasticity (Kumar et al., 2005) in rat
and in a mouse model of depression and antidepressant
treatment (Tsankova et al., 2006). In addition, zinc ﬁnger
transcription factor REST/NRSF (Chong et al., 1995;
Schoenherr and Anderson, 1995), which recruits multiple
cofactors including HDAC1, HDAC2, and mSin3A (for
review see Ballas and Mandel, 2005) to repress its target
genes, negatively regulates BDNF gene expression by
binding to NRSE/RE1 element in BDNF promoter II
(Palm et al., 1998; Timmusk et al., 1999; Bruce et al.,
2004; Ballas et al., 2005). The present study showed that
the DNA demethylating agent 5AzadC evoked robust
activation of BDNF gene expression in C6 rat glioma cells
and more moderate activation in Neuro2A mouse neuro-
blastoma cells in a transcript-speciﬁc manner: induction of
exon I, III, IV, V, VIII, and IXA mRNAs was observed in
C6 cells, whereas only exon I and exon III mRNA levels
increased in Neuro2A cells. Furthermore, in C6 cells, inhi-
bition of histone deacetylation by TSA up-regulated the
levels of BDNF exon III, exon VII, and exon IX tran-
scripts. The results presented in this study suggest the con-
tribution of histone modiﬁcations and methylation of
BDNF promoters to the regulation of BDNF gene tran-
scription and open up possibilities for addressing these phe-
nomena in more detail.
Finally, we report that, in contrast with the human
BDNF gene locus (Liu et al., 2005), mouse and rat
BDNF gene loci do not encode antisense mRNA tran-
scripts. These ﬁndings demonstrate that regulation of
BDNF gene expression by antisense-BDNF transcripts
clearly is a human- or primate-speciﬁc phenomenon and
suggest that regulation of rodent and human BDNF gene
differs substantially. Human-speciﬁc antisense transcripts
have been reported for the tumor suppressor gene ret ﬁn-
ger protein 2 (RFP2; Baranova et al., 2003) and for the
human protocadherin (PCDH) locus (Lipovich et al.,
2006). BDNF has important roles in development, partic-
ularly of the nervous system, and plays a central role in
brain plasticity-related processes, underscoring the possi-
ble role of antisense BDNF gene in regulation of BDNF
expression across primates manifesting in speciﬁc behav-
ioral phenotypes.
During the preparation of this paper, an article by
Liu and colleagues examining the gene structure and ex-
pression of BDNF in rodents was published (Liu et al.,
2006). However, our study increases the understanding of
rodent BDNF gene loci, in that we present several novel
data that are complementary to the results of Liu and col-
leagues. 1) We identiﬁed an additional 50 exon, exon V
that was not been reported by Liu et al. Thus, both mouse
and rat BDNF genes consist of at least eight 50 exons
spliced to the 30 coding exon. In addition, we identiﬁed a
novel BDNF transcript, exon IXA mRNA, consisting of
only the 50 extended protein coding exon. 2) We deter-
mined the transcription initiation sites for novel exons (III,
V, VII, VIII, and IXA), showing that these exons are tran-
scribed from distinct promoters. 3) Our data show that
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separate promoter. Liu and colleagues’ data argue that tran-
scripts containing exons VII and VIII (exons VI and VII
according to Liu et al.) share the same promoter. 4) Our
expression analysis data for all BDNF transcripts includes a
wider range of tissues and brain structures analyzed both in
rat and in mouse. 5) Liu et al. studied the regulation of
some BDNF transcript expression in brain upon adminis-
tration of cocaine. Our data show activity-dependent reg-
ulation of rat BDNF mRNAs by kainic acid-induced seiz-
ures in rat hippocampus. Moreover, we report differential
regulation of the expression of BDNF transcripts by DNA
methylation and histone deacetylation. Taken together,
the results of the present study on mouse and rat BDNF
gene structure and tissue-speciﬁc expression provide new
challenges and opportunities to identify mechanisms regu-
lating the activity of novel BDNF promoters that contrib-
ute to the expression levels of BDNF and possibly also to
the changes in BDNF expression in neurodegenerative
and neuropsychiatric disorders.
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